Strengthening development
Dr Sonya Montgomery joined OSE Immunotherapeutics SA, based in Nantes, France, as Chief Development Officer.
In her new role as CDO, Sonya Montgomery will oversee development activities for the company’s key products and the strategic development of the preclinical and clinical product portfolio, coordinating development efforts in the areas of manufacturing, supply, translational and biomarker development, alliance and medical marketing. Montgomery has held various global leadership positions at Pfizer (Connecticut and Cambridge, USA), ProQR (Netherlands), Gyroscope Therapeutics (London, UK) and most recently, as Chief Medical Officer at Evox Therapeutics (Oxford, UK).
Technologiepark Heidelberg
Collaborate Drug Discovery Inc.